Identifying Genetic Mutations in Lobular Breast Cancer Patients
Official title: LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Run by European Institute of Oncology · NCT05410951 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to find out how common certain genetic mutations are in patients with lobular breast cancer to see if these findings can help guide their future care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | Women only |
| Enrollment | 800 (estimated) |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT05410951 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with invasive lobular breast cancer or lobular in situ neoplasia who have available blood samples in a biobank.
✕Probably not a fit
Patients with previous cancers (other than skin basal cell carcinoma) or those diagnosed with ductal or mixed breast cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with invasive lobular breast cancer or lobular in situ neoplasia. It aims to identify the frequency of germline mutations using a comprehensive panel of 113 genes through Next Generation Sequencing technology. If novel mutations are discovered, personalized follow-up care or prophylactic mastectomy will be offered based on the mutation's penetrance. Patients will undergo regular screenings and follow-ups for five years to monitor their health.
Why it matters
Potential benefit: If successful, this study could lead to better personalized treatment options and preventive measures for patients with lobular breast cancer.
How similar studies have gone: While this approach is novel in its specific focus on lobular breast cancer, similar studies have successfully identified genetic mutations in other breast cancer types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. All LBC observed retrospectively at the European Institute of Oncology, with a proved diagnosis of LBC (biopsy or operated) 2. Patients with blood available in biobank Exclusion criteria * Patients with a previous cancer (except skin basal cell carcinoma) * Patients with ductal or mixed BC
Where it's running
-
European Institute of Oncology
Milan, Italy Recruiting
Study contacts
- Principal investigator: Giovanni Corso, PhD, MD — European Institute of Oncology
- Study coordinator: Giovanni Corso, PhD
- Email: giovanni.corso@ieo.it
- Phone: +390294375161
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Platform for women with BRCA1 or BRCA2 mutations in Italy
This project will try to collect clinical and follow-up data from women in Italy who carry pathogenic BRCA1 or BRCA2 mutations to build a national registry that can guide prevention and care.
-
Hormone replacement after risk-reducing salpingo-oophorectomy
This trial will test whether adding a short educational video to usual counseling helps premenopausal people with BRCA1 or BRCA2 mutations who are planning risk-reducing salpingo-oophorectomy decide about hormone replacement therapy.
-
Testing axatilimab with olaparib for advanced HER2-negative breast cancer with specific gene mutations
This study is testing a new drug called axatilimab combined with olaparib to see if it helps people with advanced HER2-negative breast cancer who have specific gene mutations.
-
Testing a new drug ETX-19477 for advanced solid tumors
This study is testing a new drug called ETX-19477 to see if it can help people with advanced solid tumors that haven't responded to other treatments.
-
Combining Elacestrant with Olaparib for Advanced Breast Cancer Treatment
This study is testing if adding elacestrant to olaparib can help people with advanced breast cancer who have specific genetic mutations live longer without their cancer getting worse.
-
Combining niraparib and irinotecan for cancers with DNA repair gene mutations
This study is testing a new combination of two cancer drugs, niraparib and irinotecan, to see if it's safe and effective for people with certain types of cancer that have DNA repair gene mutations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.